Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

• Principais autores: Beate Schmoele-Thoma (Autor), Martin van Cleeff (Autor), Richard N. Greenberg (Autor), Alejandra Gurtman (Autor), Thomas R. Jones (Autor), Vani Sundaraiyer (Autor), William C. Gruber (Autor), Daniel A. Scott (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...